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Abstract
Introduction: Although breast cancers expressing estrogen receptor-a (ERa) and progesterone receptors (PR) are
the most common form of mammary malignancy in humans, it has been difficult to develop a suitable mouse
model showing similar steroid hormone responsiveness. STAT transcription factors play critical roles in mammary
gland tumorigenesis, but the precise role of STAT1 remains unclear. Herein, we show that a subset of human
breast cancers display reduced STAT1 expression and that mice lacking STAT1 surprisingly develop ERa+/PR+
mammary tumors.
Methods: We used a combination of approaches, including histological examination, gene targeted mice, gene
expression analysis, tumor transplantaion, and immunophenotyping, to pursue this study.
Results: Forty-five percent (37/83) of human ERa+ and 22% (17/78) of ERa- breast cancers display undetectable
or low levels of STAT1 expression in neoplastic cells. In contrast, STAT1 expression is elevated in epithelial cells
of normal breast tissues adjacent to the malignant lesions, suggesting that STAT1 is selectively downregulated
in the tumor cells during tumor progression. Interestingly, the expression levels of STAT1 in the tumor-
infiltrating stromal cells remain elevated, indicating that single-cell resolution analysis of STAT1 level in primary
breast cancer biopsies is necessary for accurate assessment. Female mice lacking functional STAT1
spontaneously develop mammary adenocarcinomas that comprise > 90% ERa+/PR+ tumor cells, and depend
on estrogen for tumor engraftment and progression. Phenotypic marker analyses demonstrate that STAT1-/-
mammary tumors arise from luminal epithelial cells, but not myoepithelial cells. In addition, the molecular
signature of the STAT1-/- mammary tumors overlaps closely to that of human luminal breast cancers. Finally,
introduction of wildtype STAT1, but not a STAT1 mutant lacking the critical Tyr701 residue, into STAT1-/-
mammary tumor cells results in apoptosis, demonstrating that the tumor suppressor function of STAT1 is cell-
autonomous and requires its transcriptional activity.
Conclusions: Our findings demonstrate that STAT1 suppresses mammary tumor formation and its expression is
frequently lost during breast cancer progression. Spontaneous mammary tumors that develop in STAT1-/- mice
closely recapitulate the progression, ovarian hormone responsiveness, and molecular characteristics of human
luminal breast cancer, the most common subtype of human breast neoplasms, and thus represent a valuable
platform for testing novel treatments and detection modalities.
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Introduction
Estrogen receptor-alpha-positive (ERa+) and progester-
one receptor-positive (PR+) breast cancer account for
approximately 60% to 70% of the breast cancer cases
diagnosed in humans [1,2]. The majority of these
tumors exhibit a molecular signature that is characteris-
tic of the luminal subtype [3]. The standard of care for
luminal breast cancer is either to inhibit ERa signaling
using selective ER modulators or to deprive the tumors
of estradiol (E2) by ovarian ablation or aromatase inhibi-
tion [4]. Despite the advances in the treatment of lumi-
nal breast cancers, progress has been hampered by a
significant deficit in murine models that fully reproduce
the hormonal responsiveness and dependency of human
ERa+/PR+ breast cancers [5-8] and that can be used to
develop better methods to follow the disease after
treatment.
STAT1 is a transcription factor that plays a critical
role in interferon (IFN) signaling [9]. Cells lacking
STAT1 respond aberrantly to IFNa/b and IFNg, and
STAT1-/- mice display immune defects rendering them
highly susceptible to infection [10,11] and tumor devel-
opment [12,13]. The latter finding shows that STAT1 is
important in manifesting the IFN-dependent, cell-extrin-
sic tumor suppressor actions of immunity (that is, the
elimination phase of cancer immunoediting [14]). Other
studies have also suggested that STAT1 can function as
a cell-intrinsic tumor suppressor by maintaining basal
expression levels of caspases [15], upregulating p27Kip1
expression [16,17], or interacting with p53 or BRCA1
[18-20]. However, these latter studies were conducted
mostly with cell lines in vitro and have not been vali-
dated by in vivo approaches. Most recently, in vivo stu-
dies indicated that STAT1 could suppress tumor
development in the ErbB2/Neu-driven mammary tumor
models [21,22], although its action in other types of
mammary tumors remains undefined. Paradoxically,
others have proposed that STAT1 can facilitate tumor
outgrowth since elevated levels of STAT1 in melanoma
cell lines result in their acquisition of resistance to
radiation or chemotherapy [23,24]. This apparent para-
dox has also been observed in biopsies of human breast
cancers [25,26]. However, it remains unclear whether
the altered STAT1 levels were present in the breast can-
cer cells themselves or in stromal cells. Thus, the phy-
siological role of STAT1 during cancer development
remains poorly understood and may be context-
dependent.
Here, we show that STAT1 expression is lost or sig-
nificantly diminished in the neoplastic cells of a subset
of human patients with ERa+/PR+ breast cancer relative
to normal breast epithelium, suggesting that downregu-
lation of STAT1 is associated with tumor progression.
To further investigate this observation, we followed
female mice lacking STAT1 longitudinally and found
that they spontaneously develop ERa+/PR+, hormone-
responsive mammary gland cancers of the luminal sub-
type, thus closely recapitulating the characteristics of
human ERa+/PR+ luminal breast cancers.
Materials and methods
Immunohistochemistry on human breast cancer samples
Formalin-fixed paraffin-embedded tissue blocks were
retrieved from the archive of the Department of Pathol-
ogy in Spedali Civili di Brescia, Brescia, Italy. This retro-
spective study was conducted in compliance with the
Declaration of Helsinki and with policies approved by the
Ethics Board of Spedali Civili di Brescia. For this large-
scale retrospective and exclusively observational study on
archival materials, patient consent was not needed, as
established by Italian regulations (Delibera del garante n.
52 del 24/7/2008 and DL 193/2003). The cohort con-
sisted of 161 primary breast carcinomas selected from a
series of routinely examined cases collected between
2006 and 2008, adjacent normal breast tissues from 11
patients with cancer, and normal breast tissues from five
healthy individuals (tissues kindly provided by Monica
Guaragni, Clinica S. Anna, Brescia, Italy). Breast carci-
noma samples were characterized on the basis of histol-
ogy, ERa (clone SP1; Thermo Fisher Scientific, Waltham,
MA, USA) and PR (clone PgR 636; Dako, Glostrup, Den-
mark) expression, and HER2 amplification by immuno-
histochemistry (Herceptest; Dako) and fluorescence in
situ hybridization (PathVision HER-2 DNA probe kit;
Abbott Laboratories, Abbott Park, IL, USA) (summarized
in Table 1). STAT1 protein expression was evaluated on
four-micron (4-μm) tissue sections by using a rabbit
polyclonal antibody against STAT1 (sc-346, 1:400; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Antigen
retrieval was performed by microwaving in citrate buffer
(pH 6.0). Positive signal was revealed by the Super Sensi-
tive polymer-horseradish peroxidase immunohistochem-
istry detection system in accordance with the
instructions of the manufacturer (BioGenex, San Ramon,
CA, USA). Mouse spleens obtained from WT and
STAT1-/- mice were used as positive and negative con-
trols, respectively, to confirm the specificity of the
STAT1 antibody (Figure 1A). STAT1 expression of the
human normal breast tissues and breast tumor samples
was assessed according to the percentage of STAT1+
tumor or stromal cells (percentage score: 1 = fewer than
5% of positive cells; 2 = 5% to 25% of positive cells; 3 =
25% to 75% of positive cells; and 4 = greater than 75% of
positive cells) and to the intensity of the staining (inten-
sity score: 1 = low; 2 = intermediate, and 3 = high) (Table
1 and Figure 1B), similar to the determination of ERa
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expression by using the Allred score [27]. The percentage
score was then added to the intensity score to produce
the final STAT1 score.
Mice
129S6/SvEvTac-Stat1tm1Rds (referred to here as STAT1-
deficient, or STAT1-/-), 129S6/SvEvTac-Stat1tm1Rds-Rag2
tm1Fwa (referred to here as STAT1-/- × RAG2-/-), and
B6.129S-Stat1tm1Dlv (referred to here as STAT1-null, or
S1N) mice were generated and previously characterized
in our laboratories [10,11,13]. RAG2-/- mice were gener-
ated by Frederick Alt [28]. Wild-type (WT) 129S6/SvEv
and STAT1-/- (129S6/SvEv) mice were purchased from
Taconic Farms (Hudson, NY, USA), and STAT1-null
mice (mixed C57BL/6-129/SvEv and pure C57BL/6)
were maintained and housed in our laboratories. Mice
were scored as tumor-bearing when they reached 10 by
10 mm in size. All animal experiments were carried out
in accordance with the guidelines of the American Asso-
ciation for Laboratory Animal Science as an approved
protocol by the Animal Studies Committees in both the
Washington University School of Medicine and New
York University. These experiments were performed in
specific pathogen-free facilities that were accredited by
the Association for Assessment and Accreditation of
Laboratory Animal Care and that were located at the
Washington University School of Medicine and New
York University School of Medicine.
Cell cultures
STAT1-/- mammary tumor cell lines, SSM1, SSM2, and
SSM3, were originated from three individual STAT1-/-
Table 1 Clinicopathological characteristics of the human patients with breast cancer in this study with STAT1 staining
results
Number (percentage)
All cases ER- ER+
Characteristics (n = 161) (n = 78) (n = 83) P value
PR expression
Negative 95 (59%) 78 (100%) 7 (8%) 2.91 × 10-38a
Positive 76 (47%) 0 (0%) 76 (92%)
HER2 IHC or FISH
Negative 129 (80%) 46 (59%) 83 (100%) 1.35 × 10-12a
Positive 32 (20%) 32 (41%) 0 (0%)
Histology groupb
A 6 (4%) 2 (3%) 4 (5%)
B 138 (85%) 71 (91%) 67 (81%) 0.2512a
C 16 (10%) 5 (6%) 11 (13%)
D 1 (1%) 0 (0%) 1 (1%)
Percentage of STAT1+ neoplastic cells (percentage score)
< 5% 17 (11%) 7 (9%) 10 (12%)
5%-25% 20 (12%) 10 (13%) 10 (12%) 0.91c
26%-75% 65 (40%) 33 (42%) 32 (39%)
> 75% 59 (37%) 28 (36%) 31 (37%)
Percentage of STAT1+ stromal cells (percentage score)
< 5% 0 (0%) 0 (0%) 0 (0%)
5%-25% 16 (10%) 2 (3%) 14 (17%) 0.006a
26%-75% 54 (34%) 26 (33%) 28 (34%)
> 75% 91 (56%) 50 (64%) 41 (49%)
STAT1 intensity in STAT1+ neoplastic cells (intensity score)
Low 54 (34%) 17 (22%) 37 (45%)
Intermediate 60 (37%) 31 (40%) 29 (35%) 0.0042c
High 47 (29%) 30 (38%) 17 (20%)
STAT1 intensity in STAT1+ stromal cells (intensity score)
Low 2 (1%) 0 (0%) 2 (2%)
Intermediate 18 (11%) 3 (4%) 15 (18%) 0.0027a
High 141 (88%) 75 (96%) 66 (80%)
aFisher exact test. bHistology group A: ductal carcinoma in situ with minor areas of invasive ductal carcinoma; group B: invasive ductal carcinoma; group C:
lobular carcinomas; group D: mixed ductal and lobular carcinomas. cChi-squared test. ER, estrogen receptor; FISH, fluoresence in situ hybridization; HER2, human
epidermal growth factor receptor 2; IHC, immunohistochemistry; PR, progesterone receptor.
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Figure 1 Immunohistochemical analysis of STAT1 expression levels in human breast cancers. (A) Immunohistochemical analysis on wild-
type (WT) and STAT1-/- spleens to confirm the specificity of the antibody against STAT1. Sections of WT or STAT1-/- spleens were stained with a
polyclonal rabbit antibody against an epitope in STAT1 which is homologous to both humans and mice. STAT1 reactivity was observed
predominantly in the lymphoid cells of the white pulp in WT spleen. However, no appreciable signal was detected in the STAT1-/- spleen.
Original magnification, 100×. Scale bars = 200 μm. (B) The staining intensity of the STAT1+ signal was evaluated by using a three-tiered scale
(low, intermediate, and high). Low, intermediate, and high STAT1 correspond to the staining intensity scores of 1, 2, and 3, respectively, in Table
2. Six cases of estrogen receptor-alpha-negative (ERa-) and six cases of ERa+ primary human breast tumors are shown here as representative
images. Original magnification, 200×. Scale bars = 100 μm.
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tumor-bearing mice and were created by mechanical
disaggregation of tissue before an overnight incubation
with collagenase type IA (200 U/mL; Sigma-Aldrich, St.
Louis, MO, USA) and insulin (10 μg/mL; Sigma-
Aldrich) in DMEM/F12/10% FBS/1% L-glutamine/1%
penicillin-streptomycin. Clusters of epithelial cells were
enriched by sedimentation through five washes of 40
mL of DMEM/F12/5% FBS each. Stromal fibroblasts
were eliminated by differential trypsinization by using
0.05% trypsin once a week over the next 2 months. The
absence of fibroblasts was determined by immunofluore-
sence by using an antibody specific for vimentin (sc-
7557; Santa Cruz Biotechnology, Inc.). The SSM cell
lines are maintained in DMEM/F12/10% FBS/1% L-glu-
tamine/1% penicillin-streptomycin/50 μM 2-mercap-
toethanol/0.3 μM hydrocortisone/5 μg/mL insulin/10
ng/mL transferrin. MCF7 and NMuMG were purchased
from American Type Culture Collection (Manassas, VA,
USA) and are cultured in DMEM/10% FBS/1% L-gluta-
mine/1% penicillin-streptomycin. The MCF7 cell line is
a human ERa+ breast cancer cell line. NMuMG is an
immortalized nontransformed murine mammary gland
epithelial cell line.
Immunohistochemistry and immunofluorescence
analyses on murine tumor samples
Tumors were harvested and fixed in 10% neutral buf-
fered formalin for 1 to 2 days. Paraffin blocks were
made, and slides were stained with hematoxylin and
eosin (H&E) for histological examination. To examine
the presence of ERa and PR, slides were deparaffinized,
serially rehydrated, and stained in accordance with the
routine procedures in the Mutant Mouse Pathology
Laboratory of the University of California at Davis. For
the immunofluoresence assay determining the presence
of fibroblasts, SSM tumor cells were plated on coverslips
and allowed to attach overnight. Cells were then fixed
and permeablized with ice-cold methanol and then acet-
one for 10 minutes each at -20°C. Coverslips were
washed extensively with 1× phosphate-buffered saline
(PBS) and blocked with 5.5% normal donkey serum and
2% bovine serum albumin in PBS. Cells were incubated
with anti-cytokeratin (anti-CK) (wide spectrum) (Z0622,
1:200; Dako) or anti-vimentin (sc-7557, 1:50; Santa Cruz
Biotechnology, Inc.) for 1 hour at room temperature.
Donkey anti-rabbit conjugated with Cy2 and donkey
anti-goat conjugated with Cy3 (1:200; Jackson Immu-
noResearch Laboratories, Inc., West Grove, PA, USA)
were used for the detection of CK and vimentin, respec-
tively. To examine the expression of ERa, tumor cells
were plated on coverslips, fixed in 4% paraformaldehyde,
and permeablized in 0.5% Triton X-100. Monoclonal
antibody against ERa (6F11, 1:40; Novocastra, now part
of Leica, Wetzlar, Germany) and donkey anti-mouse
conjugated with Cy3 were used. DAPI (4’-6-diamidino-
2-phenylindole) was used to identify nuclei in all immu-
nofluoresence assays (Molecular Probes, now part of
Life Technologies, Grand Island, NY, USA).
Southern blotting
Southern blot analysis was performed as described pre-
viously [29]. The probe was prepared by digesting a
plasmid containing the MMTV long terminal repeat
with BamHI (the MMTV-LTR plasmid was a generous
gift from Elena Buetti of the Swiss Institute for Experi-
mental Cancer Research in Switzerland) [30].
MTT
MCF7, SSM1, SSM2, or SSM3 was plated in 96-well
plates in phenol red-free media with 10% charcoal-trea-
ted FBS (HyClone, Logan, UT, USA) supplemented with
hydrocortisone, insulin, and transferrin and with or
without 10 nM 17-b-estradiol (Sigma-Aldrich). Cell pro-
liferation was determined by using 3-(4,5-dimethyl-2-
thiazlyl)-2,5-diphenyl-2H-tetrasolium bromide (MTT)
assays in accordance with the instructions of the manu-
facturer (Promega Corporation, Madison, WI, USA).
Western blotting
SSM1, SSM2, SSM3, and NMuMG cells were lysed in
RIPA buffer (R0278; Sigma-Aldrich) with 2 mM sodium
vanadate, protease inhibitor cocktail (P8340, 1:500;
Sigma-Aldrich), and phosphatase inhibitor cocktail
(P5726, 1:100; Sigma-Aldrich). Cleared lysate (200 μg)
was resolved on SDS-PAGE and transferred onto nitro-
cellulose membranes. ERa expression was detected by
incubating blots with the monoclonal antibody 6F11
against ERa (VP-E613, 1:500; Vector Laboratories, Bur-
lingame, CA, USA). PR expression was examined with a
PR antibody against the C terminus of both PR-A and
PR-B (sc-538, 1:500; Santa Cruz Biotechnology, Inc.).
Ovariectomy and tumor transplantation
Female WT or STAT1-/- mice were either sham-oper-
ated or ovariectomized at 6 to 8 weeks of age under
general anesthesia. Two weeks after the surgery, 105
SSM1, SSM2, or SSM3 mammary tumor cells in 10 μL
were injected into the inguinal fat pads of the mice.
Alternatively, tumor fragments of about 1 mm in size
were transplanted into the inguinal fat pads. Tumor
growth was monitored by palpation once every 3 to 6
days and measured at two perpendicular diameters. The
average of the two perpendicular measurements was
plotted. In experiments in which exogenous E2 was sup-
plemented to ovariectomized mice, 60-day release E2
pellets at 0.5 mg per pellet were used (Innovative
Research of America, Sarasota, FL, USA). In the endo-
crine treatment experiment, nu/nu mice or STAT1-/-
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mice were transplanted with 106 SSM3 tumor cells or
tumor fragments, respectively. When the established
tumors reached 5 mm in diameter, the animals were
either sham-operated or ovariectomized. Tumor growth
was monitored as described above.
Immunophenotypic analyses on STAT1-/- mammary
glands
Mammary glands were harvested from 10- to 14-month-
old STAT1-/- female mice and digested in collagenase and
hyaluronidase solution, as described in [31]. Single-cell sus-
pension was prepared after dissociated tissues were treated
with trypsin/DNase for 1 minute and dispase/DNase for 2
minutes and passed through 40-μm cell strainers. Cells
were first blocked with anti-CD16 and anti-CD32 Fcg
receptors and normal rat serum and then stained with
anti-TER119-PE/Cy7 (BioLegend, San Diego, CA, USA),
anti-CD31-PE/Cy7 (BioLegend), anti-CD45-PE/Cy7 (Bio-
Legend), anti-CD24-APC (BioLegend), or anti-CD49f-bio-
tin (BioLegend) for 20 minutes at 4°C. Streptavidin-APC/
Cy7 (BioLegend) was added, and cells were incubated for
20 minutes at 4°C. Stained cells were collected by using an
LSRII flow cytometer (BD Biosciences, San Jose, CA, USA).
Dead cells were gated out by using DAPI (Invitrogen Cor-
poration). Cells depleted of CD31, CD45, and TER119
were further analyzed on the basis of their CD49f and
CD24 surface expression. Myoepithelial cells were defined
as CD49fhi CD24int, whereas luminal epithelial cells were
CD49fint CD24hi, as established previously [31-33]. Flow
cytometry profiles were analyzed by using FloJo software
(TreeStar Inc., Ashland, OR, USA).
STAT1 reconstitution
Retrovirus expressing GFP alone, STAT1.IRES.GFP, and
STAT1 mutants Y701F.IRES.GFP and S727A.IRES.GFP
was prepared by co-transfecting Phoenix cells with the
retrovirus plasmid and pCMV.VSVg by using FuGENE
HD (Roche, Basel, Switzerland). Supernatant was har-
vested 48 and 72 hours after transfection and overlayed
on NMuMG, SSM1, SSM2, or SSM3 cells in the pre-
sence of 8 μg/mL of polybrene for 6 to 8 hours. Infec-
tion was carried out for 2 consecutive days. The
infected cells were harvested on day 2 after infection for
Western blotting to confirm expression and on day 3
for flow cytometry to quantitate the percentages of cells
undergoing early apoptosis. Apoptosis was measured by
a flow cytometry-based annexin V-binding assay in
accordance with the instructions of the manufacturer
(BD Biosciences). Only the early apoptotic cells (annexin
V-positive, 7AAD-negative) were analyzed.
Gene expression profiling analysis
Total RNAs were isolated from normal mammary
glands of primary STAT1-/- mammary tumors by using
Trizol in accordance with the procedure of the manu-
facturer (Invitrogen Corporation). RNA integrity was
confirmed by using an Agilent bioanalyzer (Agilent
Technologies, Inc., Santa Clara, CA, USA). Labeled tar-
get cRNAs were synthesized and hybridized to Affyme-
trix GeneChip MOE 430 2.0 arrays in accordance with
the instructions of the manufacturer. Raw data were
modeled and normalized by using dChip [34]. Well-
annotated mouse and human orthologs were identified
by using the Mouse Genome Informatics database [35],
and medians were used in cases of redundant probesets.
The Herschkowitz data matrix contains 232 human
breast cancer datasets and 122 murine datasets from 13
different mammary tumor models, which were analyzed
by using 106 intrinsic genes common to the two species
[36]. To combine our STAT1-/- mammary tumor data-
sets with the Herschkowitz datasets, 96 of the 106
intrinsic genes were used because of platform differ-
ences. Gene-wise normalization was carried out sepa-
rately with each dataset such that each gene has median
zero and unit standard deviation. Distance-weighted dis-
crimination (DWD) was used to merge our datasets
with the Herschkowitz datasets to eliminate large sys-
tematic biases arising from different RNA purification
procedures and distinct microarray platforms [37,38].
For unsupervised cluster analysis, the average linkage
hierarchical clustering algorithm was then applied to the
merged datasets by using XCluster [39] with the cen-
tered correlation coefficient as the similarity/dissimilar-
ity metric. The gene expression heatmap and
dendrogram were generated in Java TreeView [40] to
visualize the relationship between the human breast
cancer subtypes and murine mammary tumor models
according to the gene expression intensities of the 96
genes. Gene expression profiling data have been depos-
ited in the National Center for Biotechnology Informa-
tion’s Gene Expression Omnibus (GEO) under accession
number GEO:GSE31942 [41].
sigClust
sigClust examines the significance of a given clustering
by testing the null hypothesis that the datasets are from
the same Gaussian distribution [42]. We applied sigClust
to five STAT1-/- primary tumor samples and 63 human
luminal breast cancer samples by using the 96-gene
intrinsic gene list. The resulting P value is 0.99998,
which indicates that the STAT1-/- mammary tumors are
highly likely to be in the same cluster with the human
luminal breast cancer datasets. In addition, we applied
sigClust on the MMTV_Neu and MMTV_PyMT data-
sets from the Herschkowitz study [36]. To avoid poten-
tial bias due to different sample sizes, we drew a set of
five samples out of these two sets of data through 200
iterations and implemented the test on the set of five
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samples and the human luminal breast cancer datasets.
The average P values were 0.9110 (MMTV_Neu), 0.9630
(MMTV_PyMT), and 0.9665 (both mouse models com-
bined). These results indicate that the STAT1-/- mam-
mary tumor model exhibits a higher degree of
resemblance to human luminal breast cancers at the
gene expression level than the MMTV-Neu and
MMTV-PyMT models do.
Consensus clustering
To investigate the stability of clustering between
STAT1-/- mammary tumors and human luminal breast
cancer, consensus clustering, which is a re-sampling-
based technique that uses perturbation to simulate a set
of new samples from the original merged dataset, was
employed [43]. Consensus index on empirical clustering
results across all perturbed datasets was then summar-
ized by the normalized proportion of times that two
samples were assigned to the same cluster. The underly-
ing assumption is that the induced cluster composition
is more trustworthy if the clustering is robust to sam-
pling variability. We re-sampled 1,000 times and consid-
ered the number of clusters ranging from two to 15 for
assessment. Using the 96-gene intrinsic gene list, we
found that the five STAT1-/- mammary tumors belong
to the same cluster 95% of the time after 1,000 re-sam-
plings with an interquartile range (IQR) of 0.9128 to
0.9775 (range = 0.8964 to 1.0), which indicates that the
STAT1-/- mammary tumors are molecularly homoge-
neous. The STAT1-/- mammary tumors and human
luminal breast cancers cluster together 62% out of 1,000
re-samplings with an IQR of 0.57 to 0.67 (range = 0.32
to 0.78). In contrast, the MMTV-Neu and MMTV-
PyMT mouse models cluster with the human luminal
breast cancer datasets only 42% out of 1,000 re-sam-
plings with an IQR of 0.44 to 0.48 (range = 0.01 to0.64).
These results further demonstrate that the molecular
signature of the STAT1-/- mammary tumors significantly
overlaps with that of human luminal breast cancers.
Statistical analyses
Time to onset was analyzed by the Kaplan-Meier pro-
duct limit method, which generated the Kaplan-Meier
survival curves. P values were reported by log-rank test.
All numerical results are presented as mean and stan-
dard error of mean and represent data from a minimum
of three independent experiments unless otherwise sta-
ted. Tumor growth curves were analyzed by a distribu-
tion-free test [44]. The unpaired t test for two
independent samples was used to determine the statisti-
cal significance between the experimental groups and
control groups. Wilcoxon signed rank test was used to
compare STAT1 intensity levels in tumor samples and
adjacent normal breast tissues. Association between
clinicopathological characteristics and ERa status was
tested by chi-squared test or Fisher exact test, whichever
was appropriate. All tests were two-sided, and a P value
of not more than 0.05 was considered significant.
GraphPad Prism (GraphPad Software, Inc., La Jolla, CA,
USA), SAS 9.2 (SAS Institute Inc., Cary, NC, USA), and
R 2.11.1 [45] were used for all statistical analyses.
Results
A subset of human breast cancers display reduced STAT1
expression in neoplastic cells
To explore the role of STAT1 in breast tumor develop-
ment, the relative cellular levels of STAT1 protein were
immunohistochemically assessed in a cohort of 161 pri-
mary breast cancer samples (78 ERa- and 83 ERa+
cases) (Table 1) by using a STAT1-specific polyclonal
IgG antibody that recognizes a STAT1 epitope shared
by the human and mouse proteins (Figure 1A). Normal
breast tissues from 11 patients with cancer and five
healthy individuals were used as nontransformed con-
trols (Table 2). STAT1 expression in epithelial cells and
infiltrating stromal cells was quantified on the basis of
the percentage of STAT1+ cells (percentage score) and
the intensity of the positive signal by using a three-
tiered scale (intensity score) (Figure 1B and Materials
and methods).
In normal human breast tissue from healthy indivi-
duals, STAT1 was detected in the cytoplasm of luminal
epithelial cells, in the nuclei of the spindle cells in the
surrounding stroma, and sporadically in myoepithelial
cells (Figure 2A). In contrast, STAT1 expression was
highly variable among tumor samples (Figures 1B, 2B,
D, and 2F), consistent with previous reports [46,47].
Specifically, in 11% of cases (17 out of 161), STAT1
expression was detectable in less than 5% of the neo-
plastic cells, whereas in 37% of cases (59 out of 161),
more than 75% of the tumor cells expressed STAT1
(percentage score in Table 1). The remaining 52% of
cases displayed an intermediate phenotype in which
STAT1 staining was observed in 5% to 75% of the neo-
plastic cells. In addition to documenting the percentage
of STAT1+ cells, we recorded the relative intensity of
the positive signal (intensity score). Thirty-four percent
of the tumor cases (54 out of 161) exhibited low STAT1
staining in the neoplastic cells, whereas 37% and 29%
showed intermediate and high staining, respectively
(Table 1). Although the percentages of STAT1+ neoplas-
tic cells in ERa- and ERa+ tumors were comparable
(percentage score in Table 1), the intensity of the stain-
ing was significantly lower in ERa+ breast cancers than
in ERa- breast cancers (intensity score in Table 1 and
summarized in Figure 2G). Specifically, 45% of the ERa+
tumors exhibited low levels of STAT1 staining in neo-
plastic cells, in contrast to 22% of the ERa- cases,
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demonstrating that reduced STAT1 expression is asso-
ciated with ERa+ tumors (Table 1 and Figure 2G). A
similar trend was observed in the stroma between ERa-
and ERa+ cases (Figure 2G). However, since STAT1 was
universally elevated in stromal cells compared with neo-
plastic cells within the same tumors (Figure 2D, F, and
quantified in Figure 2G), the difference in stromal
STAT1 intensity between ERa- and ERa+ cases is unli-
kely to be functionally meaningful. These findings thus
indicate that STAT1 expression is differentially regu-
lated in epithelial versus stromal compartments.
In contrast to the observation that lower STAT1
expression levels were associated with ERa+ breast can-
cers versus ERa- cancers, there was no significant asso-
ciation between low STAT1 expression and HER2 status
(Table 3). HER2- and HER2+ breast cancers displayed
similar percentages of STAT1+ cells and levels of
STAT1 intensity in the stromal and neoplastic compart-
ments (Table 3). When these data are taken together,
the lowest level of STAT1 expression is preferentially
associated with the ERa+ breast cancer subtype.
Since STAT1 is uniformly expressed in the luminal
epithelial cells of breast tissues from normal healthy
individuals, the observation that a large subset of breast
cancer cases exhibit low levels of STAT1 expression
suggests that STAT1 may be downregulated specifically
in the neoplastic cells. To further investigate this possi-
bility, STAT1 expression was also assessed in morpholo-
gically normal breast tissues of patients with breast
cancer. In all of the 11 STAT1-low breast cancer cases
in which adjacent normal breast tissues were available,
normal breast tissues had significantly more STAT1+
epithelial cells and exhibited stronger staining intensity
than matched tumor tissues (Figure 2C-F and Table 2).
This resulted in an overall higher STAT1 score in nor-
mal epithelial cells than in breast tumor cells (Figure
2H). These findings thus demonstrate that STAT1
expression is dramatically diminished or lost in a signifi-
cant proportion of breast cancer cells during tumor
progression.
STAT1-/- mice are highly susceptible to mammary tumor
formation
The findings that diminished STAT1 expression is asso-
ciated with breast cancer progression prompted us to
investigate whether loss of STAT1 was a cause, not
merely a consequence, of mammary tumorigenesis. We
monitored WT and STAT1-/- 129S6/SvEv-strain female
mice for tumor development and found that 65% (15
out of 23) of the STAT1-/- mice developed spontaneous
mammary adenocarcinomas (median tumor onset of 23
months) but that none of the WT mice developed the
disease (Figure 3A). In agreement with our previous
report [13], we observed mammary tumor development
in a larger cohort of STAT1-/- × RAG2-/- female mice in
similar disease incidences (Figure 3A). STAT1-/- mice
developed mammary tumors only, whereas STAT1-/- ×
RAG2-/- mice developed mammary and intestinal
tumors. Mice lacking RAG2 alone did not develop
mammary tumors (Figure 3A), demonstrating that this
Table 2 Summary of the STAT1 staining results on normal breast tissues and paired breast tumors
Normal breast tissues Breast tumors












HN1 NA 4 2 6 NA NA NA
HN2 NA 4 1 5 NA NA NA
HN3 NA 4 2 6 NA NA NA
HN4 NA 3 1 4 NA NA NA
HN5 NA 4 2 6 NA NA NA
87 + 4 2 6 1 1 2
160 + 4 2 6 1 1 2
84 + 4 2 6 1 1 2
147 + 4 2 6 1 1 2
80 + 4 2 6 1 1 2
115 + 4 2 6 1 1 2
161 + 3 2 5 1 1 2
58 - 3 1 4 1 1 2
20 - 3 1 4 1 1 2
53 - 4 2 6 1 2 3
47 - 4 2 6 1 2 3
Normal breast tissues from healthy individuals: HN1, HN2, HN3, HN4, and HN5. Paired tumor samples with adjacent normal breast tissues: case 87, 160, 84, 147,
80, 115, 161, 58, 20, 53, and 47. aEstrogen receptor-alpha (ERa) expression in breast tumors. bPercentage score: 1, < 5%; 2, 5%-25%; 3, 26%-75%; 4, > 75%.
cIntensity score: 1 = low, 2 = intermediate, 3 = high. dSTAT1 score = percentage score + intensity score. +, positive; -, negative; NA, not applicable.
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Figure 2 Selective downregulation of STAT1 expression in the neoplastic cells of human breast tumors. (A) Representative image of
STAT1 staining on normal breast tissues of healthy individuals (n = 5) shows STAT1 expression in luminal epithelial cells and stromal cells and
occasionally in myoepithelial cells. Original magnification, 100×. Scale bar = 200 μm. Inset, 400×. (B) Representative image of a breast tumor case
with high levels of STAT1 expression in both the epithelial and stromal compartments. Original magnification, 200×. Scale bar = 100 μm. Inset,
400×. (C-F) Representative images of paired adjacent normal breast tissues (left) with breast tumors (right; n = 11). Morphologically normal
breast tissues from patients with breast cancer display a STAT1 expression pattern that is similar to that in normal breasts from healthy
individuals (C, E). Panel (C) is the paired normal tissue of the tumor in panel (D) (case 87), whereas panel (E) is the paired normal tissue of the
tumor in panel (F) (case 58). The epithelial tumor cells of the representative estrogen receptor-alpha-positive (ERa+) (D) and ERa- (F) breast
cancers were devoid of STAT1 expression, whereas STAT1 level remained high in the tumor stroma. Original magnification, 200×. Scale bars =
100 μm. (G) Intensity scores of the neoplastic and stromal cells of all cases (n = 161) are plotted. Reduced STAT1 staining intensity was
preferentially associated with ERa+ human breast cancers relative to ERa- breast cancers in both the neoplastic and stromal compartments (P =
0.001, unpaired t test). Stromal cells had an overall higher STAT1 expression level than the neoplastic cells of the same tumors (P < 0.0001,
Wilcoxon signed rank test). (H) Breast tumors exhibited significant reduction in STAT1 score in comparison with matched normal breast tissues
(n = 11) (P = 0.003, Wilcoxon signed rank test). STAT1 score is the sum of the score representing the percentages of STAT1+ cells (percentage
score) and that representing the STAT1 staining intensity (intensity score).
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phenotype is specifically associated with STAT1 defi-
ciency. Cells from our STAT1-/- mice express low levels
of a nonfunctional truncated STAT1 protein and are
incapable of responding to IFN either in vitro or in vivo
[10,48]. Nevertheless, by examining STAT1-null (S1N)
mice generated by using a different targeting strategy
and different embryonic stem cells that were maintained
on a mixed C57BL/6-129/SvEv background, we ruled
out the possibility that this truncated protein is involved
in disease development [11]. Female S1N mice also
developed spontaneous mammary tumors with a median
tumor onset of 14.5 months (Figure 3A). Although the
S1N mice exhibited a shorter latency than the 129S6/
SvEv STAT1-/- mice, the penetrance of the two cohorts
was indistinguishable and the difference in the overall
tumor incidences was not statistically significant (P =
0.26). These results demonstrate the generality of the
phenotype to mice lacking functional STAT1, regardless
of targeting strategy or mouse strain. STAT1-/- mice
that were sterilely re-derived and housed exclusively in a
Table 3 Summary of the STAT1 staining results in the estrogen receptor-negative human breast cancer cohort
stratified by HER2 status
Number (percentage)
All ER- cases HER2- HER2+
Characteristics (n = 78) (n = 46) (n = 32) P value
Percentage of STAT1+ neoplastic cells (percentage score)
< 5% 7 (9%) 4 (9%) 3 (10%)
5%-25% 10 (13%) 8 (17%) 2 (6%) 0.14a
26%-75% 33 (42%) 22 (48%) 11 (34%)
> 75% 28 (36%) 12 (26%) 16 (50%)
Percentage of STAT1+ stromal cells (percentage score)
< 5% 0 (0%) 0 (0%) 0 (0%)
5%-25% 2 (3%) 2 (4%) 0 (0%) 0.2a
26%-75% 26 (33%) 18 (39%) 8 (25%)
> 75% 50 (64%) 26 (57%) 24 (75%)
STAT1 intensity in STAT1+ neoplastic cells (intensity score)
Low 17 (22%) 10 (22%) 7 (22%)
Intermediate 31 (40%) 19 (41%) 12 (38%) 0.96b
High 30 (38%) 17 (37%) 13 (40%)
STAT1 intensity in STAT1+ stromal cells (intensity score)
Low 0 (0%) 0 (0%) 0 (0%)
Intermediate 3 (4%) 0 (0%) 3 (10%) 0.07a
High 75 (96%) 46 (100%) 29 (90%)
aFisher exact test. bChi-squared test. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2.
Figure 3 Spontaneous development of mammary gland adenocarcinomas in STAT1 deficient (STAT1-/-), STAT1 null (S1N), and STAT1-/-
× RAG2-/- female mice. (A) STAT1-/- (n = 23, inverted red triangles), S1N (n = 26, inverted purple triangles), and STAT1-/- × RAG2-/- (n = 31, blue
squares) mice succumbed to mammary tumors, whereas none of the age-matched wild-type (WT) 129S6/SvEv (n = 41, black triangles) or RAG2-/-
(n = 33, yellow circles) mice developed the disease. P values were obtained with log-rank test by comparing STAT1-/- × RAG2-/- with WT mice
(***P = 0.0003) and STAT1-/- or S1N with WT mice (****P < 0.0001). Curves between STAT1-/- and S1N mice are not different to a statistically
significant degree (P = 0.24). (B) Multiparous STAT1-/- mice (n = 11, red) developed mammary tumors at a higher frequency and with shorter
latency than nulliparous STAT1-/- mice (n = 12, black) (P < 0.0001).
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commercial gnotobiotic facility also developed mam-
mary tumors, a result suggesting that the disease was
not of infectious origin. This conclusion was substan-
tiated by viral microarrays [49] that failed to detect
either known or novel viruses in mammary tumors or
other tissues of STAT1-/- mice and by the lack of evi-
dence for translocation and additional chromosomal
integration of endogenous mammary tumor proviruses
in these tumors (Figure S1 in Additional file 1).
Since tumor development did not reach a complete
penetrance in the STAT1-/- and S1N mice, we examined
whether parity might influence tumorigenesis. Strikingly,
multiparous STAT1-/- mice developed mammary tumors
sooner and at a higher frequency than nulliparous
STAT1-/- mice (Figure 3B). Specifically, multiparous
mice had a median tumor onset of 14.8 months versus
24.6 months of nulliparous mice. Most importantly, the
incidence of tumor development was 91% (10 out of 11)
in mice that had undergone multiple rounds of preg-
nancy and lactation compared with 62% of nulliparous
mice. Taken together, these data suggest that preg-
nancy-associated hormones might accelerate mammary
tumor formation in STAT1-/- mice.
STAT1-/- mammary tumors display homogeneous
expression of estrogen receptor-alpha
Examination of whole mounts of mammary gland tis-
sues from 12- to 24-month-old female STAT1-/- mice
without palpable masses revealed focal atypias in about
50% of the cohort (n = 19) (Figure 4A, B). This abnorm-
ality was not observed in mammary glands of age-
matched WT female mice (n = 12). The early lesions in
STAT1-/- mammary glands varied from distended ducts
to small cystically dilated clusters of alveoli (Figure 4B).
Analysis of the H&E-stained tissue sections revealed
that these abnormal foci contained atypical cells fulfill-
ing the criteria for mammary intraepithelial neoplasia
(MIN) (Figure 4C, D) [50]. Surprisingly, atypical nuclei
in MIN lesions stained positively for ERa and PR (Fig-
ure 4E-H). Similar analyses of overt tumors revealed the
presence of solid nests of neoplastic ERa+ or PR+ cells
with frequent central necroses (Figure 4I-N). Over 90%
of all tumor cells expressed ERa (Figure 4K, L). Some
tumors had invasive nests of neoplastic cells with areas
of fibrosis and inflammation (Figure 4I, J). All primary
STAT1-/- mammary tumors examined, regardless of par-
ity, showed similar histopathological characteristics and
patterns of hormone receptor expression. None of the
primary tumors stained positively for HER2 (data not
shown). Thus, mammary tumors in STAT1-/- mice pro-
gress developmentally from intraepithelial neoplasia to
carcinoma in a manner that is remarkably similar to the
progression from ductal carcinoma in situ to invasive
ductal carcinoma seen in the human disease [51]. Since
spontaneous ERa+/PR+ mammary tumors are rarely
observed in mice, our findings also suggested that
STAT1-/- mice may represent a relatively novel model
for human ERa+/PR+ luminal breast cancer.
Ovarian hormone dependency of STAT1-/- mammary
tumor cells
To facilitate biological and biochemical characterization
of the STAT1-/- mammary tumors, three tumor cell
lines were established and designated spontaneous
STAT1-/- mammary (SSM) epithelial tumor cell lines
(SSM1, SSM2, and SSM3). All expressed CK but not
vimentin in vitro, documenting their epithelial origin
(Figure S2 in Additional file 2). SSM2 and SSM3
expressed nuclear ERa, which is similar to the human
ERa+ breast cancer cell line, MCF7 (Figure 5A). SSM2
and SSM3 also expressed the two PR isoforms, PR-A
and PR-B (Figure 5C), suggesting that ERa is functional
in these cells. In contrast, SSM1 expressed a very low
level of ERa (Figure 5B) and no detectable PR-A/PR-B
expression (Figure 5C), indicating a lack of ERa signal-
ing in the SSM1 cells. Whereas SSM2 and SSM3
required the presence of estrogen to proliferate in vitro,
SSM1 did not (Figure 6A). Finally, when transplanted
into the fat pads of WT or STAT1-/- mice, SSM2 and
SSM3 grew only in recipients with intact ovaries or in
ovariectomized recipients that received subcutaneous
estrogen pellet implants (Figure 6B). In contrast, SSM1
did not require ovarian hormones for in vivo growth
(Figure 6B), revealing that not all STAT1-/- mammary
tumor cells display hormone dependency. This result
corresponds with the finding that most, but not all,
tumor cells in the primary STAT1-/- mammary carcino-
mas display ERa and PR positivity (Figure 4). However,
these hormone-independent cells are extremely rare in
the primary STAT1-/- mammary tumors as demon-
strated by the fact that tumor fragments from two inde-
pendent primary tumors failed to engraft in
ovariectomized mice (Figure 6C). Together, these results
demonstrate that SSM2 and SSM3 are ovarian hor-
mone-responsive and -dependent in vitro and in vivo
and that SSM1 arises from a very rare subset of ERa-
cells and is used in this study as a hormone-nonrespon-
sive cell line.
Having demonstrated that the STAT1-/- ERa+ mammary
tumor cells required ovarian hormones for establish-
ment of tumor growth, we next examined whether these
tumors also depended on ovarian hormones to maintain
tumor progression. We used ovariectomy as the treat-
ment modality since ovarian ablation is commonly used
to treat premenopausal patients with ERa+/PR+ breast
cancers [52]. Established SSM3 tumors continued to
grow in sham-treated mice (Figure 6D). However, estab-
lished tumors failed to progress after ovariectomy,
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indicating that the STAT1-/- ERa+/PR+ tumor cells
require ovarian hormones not only for in vivo engraft-
ment but also for maintenance of growth. Tumors that
were established from transplanted primary tumor frag-
ments were also highly sensitive to ovarian hormone
deprivation and became unpalpable upon ovariectomy
(Figure 6E). Thus, the STAT1-/- mammary tumors are
functionally similar to human ERa+/PR+ breast cancers.
STAT1-/- mammary tumors display a surface marker
phenotype reflective of luminal mammary tumors
Hormone receptor expression is one of the critical
parameters used to determine the suitable treatments
for human patients with breast cancer [2]. In addition
to hormone receptors, mammary tumors can be classi-
fied by biomarkers that are expressed on the tumor
cell surface. Myoepithelial and luminal epithelial cells
can be identified on the basis of the well-established
differential expression of murine mammary epithelial
cell population markers, CD49f and CD24 (that is,
myoepithelial cells = CD49fhi CD24int and luminal
epithelial cells = CD49fint CD24hi) [31-33]. These two
epithelial cell populations could be readily differen-
tiated in nontransformed mammary glands of STAT1-/-
mice (’myo’ and ‘lum’ in Figure 7B) by flow cytometry
upon elimination of dead cells and lineage-positive
cells (Figure 7A). Marked expansion of the luminal
epithelial cell subset was evident in MIN, the earliest
stage of neoplastic changes identifiable by histology, in
comparison with nontransformed mammary glands
(Figure 7B). Further expansion of these luminal epithe-
lial cells continued as MIN progressed to carcinomas
Figure 4 Histopathological analyses of the mammary gland carcinomas developed in STAT1-/- mice. Histopathological analyses of the
early lesions (A-H) and the invasive adenocarcinomas (I-N) in mammary glands of STAT1-/- mice. (A, B) Whole-mount images of a thoracic
mammary fat pad show aberrant dilation of mammary ducts and clusters of cystic alveoli (arrow and arrowhead). Panel (B) is a magnified image
of panel (A). Scale bars = 1 mm. (C-H) Histology of the cluster of cysts shown in panel (B), highlighted by an arrow in panel (B), demonstrated
mammary intraepithelial neoplasia (MIN). (C, D, I, J) Sections were stained with hematoxylin and eosin (H&E). Solid nests of neoplastic cells with
areas of necrosis and invasion are evident in the carcinomas (I, J). (E-H, K-N) Atypical cells in MIN lesion and neoplastic cells expressed estrogen
receptor-alpha (ERa) (E, F, K, L) and progesterone receptor (PR) (G, H, M, N). (C, E, G, I, K, M) Scale bars = 100 μm. (D, F, H, J, L, N) Higher
magnification of the corresponding left panels. Scale bars = 40 μm.
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Figure 5 STAT1-/- mammary tumor cell lines SSM2 and SSM3 express estrogen receptor-alpha (ERa), PR-A, and PR-B. (A) SSM2 and
SSM3 expressed nuclear ERa, similar to the human ERa+ breast cancer cell line MCF7. In contrast, NMuMG and SSM1 did not exhibit nuclear
ERa staining. Scale bars = 40 μm. (B) SSM2 and SSM3 are positive for ERa expression, but SSM1 expressed a very low level of ERa, by Western
blot analysis. NMuMG exhibited no detectable levels of ERa. (C) SSM2 and SSM3 expressed PR-A and PR-B, which are derived from alternative PR
promoters and are target genes for ERa signaling, suggesting that SSM2 and SSM3 were estrogen-responsive. In contrast, NMuMG and SSM1 did
not display functional ERa signaling. DAPI, 4’-6-diamidino-2-phenylindole; SSM, spontaneous STAT1-/- mammary (epithelial tumor cell line).
Chan et al. Breast Cancer Research 2012, 14:R16
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(Figure 7B). Neoplastic cells in carcinomas homoge-
neously displayed a CD49fint CD24hi phenotype. Con-
sistent with this result, primary STAT1-/- mammary
tumors are strongly positive for the luminal epithelial
markers, CK19 and CK8/18 (Figure 7C). Occasional
CK5+, CK14+, or p63+ myoepithelial cells were
observed (Figure 7C and data not shown). Together,
these results indicate that the STAT1-/- mammary
tumor cells exhibit a marker phenotype that is charac-
teristic of luminal epithelial cells.
Figure 6 STAT1-/- mammary tumors respond to and depend on ovarian hormones for engraftment and tumor progression. (A) SSM1,
SSM2, SSM3, or MCF7 was plated in phenol red-free media containing charcoal-treated fetal calf serum in the presence (17b-estradiol, or E2;
black triangles) or absence (mock; red squares) of 10 nM E2. P values were obtained with t test comparing mock-treated and E2-treated samples.
(B) SSM1, SSM2, or SSM3 (105 cells per mouse) was transplanted into the inguinal mammary glands of sham-treated (black triangles),
ovariectomized (red squares), or ovariectomized wild-type or STAT1-/- mice that were supplemented with E2 pellets (blue circles). P values were
obtained with t test comparing tumor growth in ovariectomized mice with that in either sham-treated or ovariectomized mice supplemented
with E2 pellets [44]. (C) Growth of tumor transplants from primary STAT1-/- mammary tumors is ovarian hormone-dependent. Fragments (1 × 1
mm2) from two primary STAT1-/- mammary tumors were transplanted into the inguinal fat pads of ovariectomized mice (red) or sham-operated
mice (black). No palpable masses were detected in ovariectomized mice. In contrast, tumors grew progressively in recipients with intact ovaries.
Results represent seven to eight mice in each group (P < 0.0001). (D) SSM3 tumor cells were transplanted orthotopically into the mammary fat
pads of nude mice. Mice bearing established tumors around 5 mm in diameter were sham-operated (black triangles; n = 7) or ovariectomized
(red squares; n = 9). SSM3 tumors failed to progress in the absence of ovarian hormones, demonstrating sensitivity to ovarian hormone
deprivation therapy (P < 0.0001). (E) Fragments of primary STAT1-/- mammary tumors were transplanted into the mammary fat pads of STAT1-/-
mice. When the established tumors reached 5 mm in diameter, the animals were either sham-operated (black triangles; n = 3) or ovariectomized
(red squares; n = 7). Transplanted primary tumors regressed after ovarian hormone deprivation (P < 0.0001). Error bars indicate standard error of
the mean. OD540, optical density at 540 nm; OVX, ovariectomy; SSM, spontaneous STAT1
-/- mammary (epithelial tumor cell line).
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Figure 7 STAT1-/- mammary tumor cells display a luminal epithelial cell phenotype. (A) Gating procedure used for the analysis of cell
surface markers. Disaggregated mammary glands or mammary tumors were collected by an LSRII flow cytometer and analyzed by using FlowJo.
Cells were first selected on the basis of size by using forward and side scatter (left panel). Single cells were then selected by forward scatter
(FSC)-A and FSC-W (middle panel). Live cells (DAPI-) and lineage- cells (Ter119-, CD31-, and CD45-) were gated for the analysis depicted in (B). (B)
Expression of CD49f and CD24 on STAT1-/- mammary epithelial cells (MECs), mammary intraepithelial neoplasia (MIN), and carcinoma.
Representative images from five STAT1-/- mice are shown. Myoepithelial (myo) and luminal epithelial (lum) are highlighted. (C)
Immunohistochemical analysis of primary STAT1-/- mammary tumors for cytokeratin (CK) 5, 14, 8/18, and 19. Mammary tumor cells were stained
positive for CK19 and CK8/18 (luminal epithelial markers) but negative for CK5 and CK14 (myoepithelial markers). Scale bar = 100 μm. DAPI, 4’-6-
diamidino-2-phenylindole.
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STAT1-/- mammary tumors exhibit human luminal breast
cancer-like molecular signatures
Perou and colleagues [3,53] reported previously that
human breast cancers could be differentiated into five
molecular subtypes (luminal A, luminal B, HER2, basal,
and normal-like) on the basis of their gene expression
profiles. Strikingly, when gene expression patterns of
mammary tumors from 13 different pre-existing mouse
breast cancer models were compared with those of 232
human breast cancers, none showed significant overlap
with human ERa+ luminal breast cancers [36]. To
extend these findings, we compared the gene expression
patterns of the aforementioned datasets (primary data
generously provided by Dr. Charles M Perou, University
of North Carolina at Chapel Hill) with those of five pri-
mary STAT1-/- ERa+ mammary tumors. Hierarchical
clustering analysis revealed that the five primary
STAT1-/- ERa+ mammary tumors not only resembled
one another but also closely resembled human luminal
breast cancers (Figure 8A). STAT1-/- ERa+ mammary
tumors also showed elevated transcription of genes
characteristic of luminal breast cancers (for example,
keratin 8, keratin 18, XBP1, GATA3, MYB, AREG, and
FOXA1) (Figure 8B). In agreement with the previous
report [36], samples from other mouse mammary tumor
models consistently clustered away from human luminal
breast cancers (Figure 8A). Finally, analyses using two
other statistical methods (sigClust [42] and consensus
clustering [43]) also supported the conclusion that
STAT1-/- ERa+ mammary tumors grouped more consis-
tently and reproducibly with human luminal breast can-
cers than any other mouse mammary tumor model (see
Materials and methods). Specifically, results from the
consensus clustering analysis indicated that the
Figure 8 Gene expression profiles of primary STAT1-/- estrogen receptor-alpha-positive (ERa+) mammary tumors show significant
overlap with that of human ERa+ luminal breast cancers. (A) Five primary STAT1-/- ERa+ mammary tumor datasets (S1_1, S1_2, S1_3, S1_4,
and S1_6; orange) were analyzed with 232 annotated human breast cancer datasets and 13 other mouse mammary tumor models (purple) by
hierarchical clustering using 96 genes known to be among those that are diagnostic for different human breast cancer subtypes [36]. Genes are
represented in rows, and datasets are represented in columns. Red represents genes that are overexpressed compared with the median, whereas
green represents genes that are underexpressed compared with the median. The STAT1-/- ERa+ mammary tumors (orange) cluster closely to the
human luminal breast cancers (blue) at the far left of the heatmap, underscoring the significant relatedness between the two cohorts. All human
samples are colored by intrinsic subtype as determined in [36]: blue = luminal, red = basal-like, pink = HER2+/ER-, yellow = claudin-low, and
green = normal breast-like. Expression values of the datasets can be found in Additional file 3. (B) Display of seven genes that are important
identifiers for the luminal subtype: KRT8, KRT18, XBP1, GATA3, MYB, AREG, and FOXA1 (from top to bottom). See Additional file 3 for the expression
values of these genes. HER2, human epidermal growth factor receptor 2.
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STAT1-/- mammary tumors and human luminal breast
cancers clustered 62% of the time upon 1,000 re-sam-
plings but that the MMTV-Neu and MMTV-PyMT
clustered with human luminal breast cancers only 42%
of the time upon 1,000 re-samplings. Together, the
STAT1-/- ERa+ mammary tumors display high molecu-
lar homogeneity and a striking similarity to human
luminal breast cancers.
A cell-autonomous role of STAT1 in suppressing
mammary tumor formation
The above observations led us to conclude that STAT1
suppresses tumor development in the mammary gland.
It is possible that STAT1 confers this role by mediating
the elimination phase of immunoediting. However, since
the immunodeficient RAG2-/- mice never developed
mammary tumors and the loss of STAT1 expression
was observed only in the neoplastic cells of human
breast cancers, we hypothesized that STAT1 might act
as a cell-intrinsic tumor suppressor in mammary epithe-
lium. We first investigated whether enforced expression
of STAT1 in STAT1-/- mammary tumor cells affected
their tumorigenic phenotype. This approach has been
used in the past to define several other tumor suppres-
sors [54]. Retroviral transduction of WT STAT1 into
SSM1, SSM2, and SSM3 resulted in expression of
STAT1 protein levels in each cell line comparable to
that in unmanipulated NMuMG (Figure 9A). Enforced
expression of WT STAT1 led to apoptosis of a substan-
tial percentage of SSM2 and SSM3 but not of SSM1 or
NMuMG (Figure 9B). Therefore, the tumor suppression
function of STAT1 is cell-autonomous.
Since phosphorylation at the tyrosine residue at posi-
tion 701 synergizes with that at the serine residue at
position 727 of STAT1 to effect the maximal transcrip-
tional activity [53,55], two STAT1 mutants, one lacking
the Tyr residue (Y701F) and one lacking the Ser residue
(S727A), were tested for their ability to induce tumor
cell death. Even when expressed at levels comparable to
those achieved with WT STAT1, the Y701F mutant was
unable to induce apoptosis when expressed in SSM2
and SSM3 (Figure 9C). In contrast, the S727A mutant
displayed an indistinguishable phenotype as the WT
STAT1. Thus, the tumor suppressor action of STAT1
requires tyrosine phosphorylation, but not serine phos-
phorylation, of STAT1.
Discussion
Current dogma, based on gene expression analyses of
intact breast cancer biopsies, holds that STAT1 mRNA
Figure 9 Tumor suppressor function of STAT1 is cell-autonomous. (A) STAT1 was ectopically expressed in SSM1, SSM2, and SSM3 by
retroviral transduction (STAT1) to levels comparable to the endogenous level in nontransduced (-) NMuMG. STAT1 was also overexpressed in
NMuMG (STAT1). Retrovirus expressing GFP alone was used as a negative control (GFP). (B) STAT1 reconstitution in SSM2 and SSM3 resulted in
4.5- and 3.5-fold increases in early apoptosis (that is, annexin V-positive, 7-AAD-negative cells) 3 days post-transduction, respectively. **P < 0.005.
(C) Tyrosine 701 is required for STAT1-mediated apoptosis in SSM2 and SSM3. Retrovirus expressing GFP, WT STAT1 (STAT1), and STAT1 mutants
(Y701F or S727A) were transduced into SSM2 and SSM3. Mutation in Y701 (Y701F) abolished the ability of STAT1 to induce cell death, whereas
that in S727 (S727A) was still capable of inducing cell death. SSM2, *P = 0.02. SSM3, *P = 0.04. P values were obtained with unpaired t test. ns,
not significant; SSM, spontaneous STAT1-/- mammary (epithelial tumor cell line).
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levels are elevated in breast cancer tissues compared
with normal breast tissues [3], leading to the hypothesis
that STAT1 might facilitate tumor outgrowth. Here, we
have presented a novel finding demonstrating a selective
loss of STAT1 expression in neoplastic epithelial cells,
but not in the surrounding stromal cells, compared with
normal mammary epithelium. Additionally, this tumor
cell-specific effect was observed more frequently in ERa
+ than in ERa- human breast cancers. Therefore, an
increase in STAT1 mRNA levels in the subset of breast
cancer cases that exhibit low STAT1 expression in the
neoplastic cells could be explained by a selective upre-
gulation of STAT1 transcription in the stromal cells
alone. Our findings thus indicate that the regulation of
STAT1 expression is cell context-dependent and a
STAT1 activation signature in whole-tumor biopsy
might not reflect the biology of the entire tumor micro-
environment. The clinical implication of these findings
is that caution should be taken in interpreting the invol-
vement of STAT1 in treatment outcomes when STAT1
activation signature in whole-tumor biopsies is used as a
prognostic indicator.
Since downregulation of STAT1 expression is
restricted to the neoplastic epithelial cells but not to the
surrounding stromal cells, somatic silencing of STAT1
transcription may occur preferentially in the breast can-
cer cells. STAT1 promoter methylation in squamous
cell carcinomas and prostate cancers has been proposed
to be a mechanism whereby STAT1 transcription is
repressed during transformation [56,57]. It is conceiva-
ble that STAT1 promoter methylation is likewise in
action during breast cancer progression. However, we
cannot eliminate the possibility that STAT1 downregu-
lation occurs at the post-transcriptional level. Investiga-
tion undertaken to differentiate these possibilities and to
determine whether STAT1 loss correlates with clinical
outcome is ongoing.
To investigate the role of STAT1 in mammary tumor-
igenesis, we employed a novel murine system that pro-
vided mechanistic insights into the physiological
consequence of loss of STAT1 expression. Specifically,
we find, much to our surprise, that STAT1-/- female
mice spontaneously develop mammary gland adenocar-
cinomas that show remarkable similarities to human
ERa+ luminal breast cancers. Pathologically, the
STAT1-/- mammary tumors progress from a preneoplas-
tic state classified as mammary intraepithelial neoplasia
to adenocarcinoma, mirroring the progression of human
breast cancer from atypical hyperplasia to ductal carci-
noma in situ and finally to invasive carcinoma. The hor-
mone receptor status of the STAT1-/- mammary tumors
also shows a remarkable parallel to human ERa+/PR+
breast cancers. Biologically, STAT1-/- mammary tumor
cells depend on ovarian hormones for both the initiation
and the maintenance of tumor growth. CD49fint CD24hi
luminal epithelial cells are enriched for hormone recep-
tor-positive cells that are rarely found in the myoepithe-
lial cell subset [58]. It is tempting to speculate that the
tumor-initiating cells in the STAT1-/- mammary tumors
reside in the luminal epithelial subset because of the sig-
nificant expansion of these cells in the preneoplastic
lesions. Future work will be focused on elucidating the
nature of these tumor-initiating cells.
The penetrance of multiparous STAT1-/- mice is
remarkably close to 100%, suggesting that pregnancy-
associated hormones can accelerate tumorigenesis. At
present, it is not possible to conclude that these hor-
mones are required for the tumorigenesis of the
STAT1-/- mammary glands since nulliparous STAT1-/-
mice also develop mammary tumors. While elucidating
the roles of pregnancy-associated hormones in mam-
mary tumorigenesis will be the target for future investi-
gation, work investigating the mechanism by which
STAT1 suppresses tumor formation has begun. We
employed a classic approach that has been used to vali-
date tumor suppressors in the past [54]. Similar to the
classic tumor suppressors, restoration of WT STAT1 in
the STAT1-/- mammary tumor cells spontaneously
causes tumor cell death. Our findings thus demonstrate
that the tumor suppressor function of STAT1 is cell-
autonomous. A mutant form of STAT1 lacking the
functionally critical Tyr 701 residue is defective in this
function, suggesting that STAT1 suppresses tumor for-
mation by regulating the transcription of its target
genes. Since phosphorylation in Ser 727 is functionally
distinct from and independent of that in Tyr 701
[55,59,60], the inability of the S727A mutant to abrogate
cell death suggests that tumor suppression mediated by
STAT1 does not require S727-dependent target genes,
like GBP-1 [55]. Although we cannot completely elimi-
nate the possibility that STAT1 can also act as an
extrinsic tumor suppressor via its ability to mediate
functional anti-tumor immunity, the cell-intrinsic effect
of STAT1 is consistent with recent studies demonstrat-
ing a role for STAT1 in suppressing ErbB2/Neu-driven
tumor formation [21,22]. Epithelial-specific deletion of
STAT1 accelerates tumor development in the ErbB2/
Neu tumor model. Therefore, STAT1 might exert a
broader tumor suppression function against multiple
oncogenic pathways. It is then noteworthy that STAT1
expression is also diminished in the neoplastic cells of
22% of the human HER2+ breast cancer cases that we
examined in this study.
Although the current repertoire of endocrine therapy
is remarkably effective in treating ERa+ breast cancers,
about 30% to 50% of the patients still suffer from recur-
rences [61-63]. Novel therapeutic targets for the treat-
ment of ERa+ breast cancers are, therefore, still needed.
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Preclinical models of human ERa+/PR+ breast cancers
are essential for the testing of new treatments. However,
only a limited number of models produce tumors that
contain a significant proportion of hormone-dependent
ERa+/PR+ tumor cells [5-8]. In addition, very little is
known about the molecular characteristics of the few
existing mouse ERa+/PR+ tumor cell lines and thus it
has not been possible to establish their genetic relation-
ship to human luminal breast cancers. In contrast,
STAT1-/- mammary tumors exhibit well-defined tumor
progression kinetics and a set of highly reproducible and
homogeneous histopathological, biological, and molecu-
lar characteristics that closely resemble human luminal
breast cancers. Most importantly, STAT1-/- mammary
tumors express elevated levels of ERa, PR, GATA3,
AREG, XBP1, and FOXA1, all of which are regulated by
the transcriptional control of ERa. In agreement with
this activated ERa genetic signature, STAT1-/- mam-
mary tumor is also a unique preclinical model because
of its sensitivity to standard endocrine therapy, including
estrogen deprivation therapy (this study) and treatment
targeting ERa (AM Fowler and MJ Welch, manuscript
in preparation). Furthermore, STAT1-/- mammary
tumor cells are transplantable orthotopically into both
immunocompetent and immunodeficient mice, facilitat-
ing the examination of immune-based therapies, which
otherwise would not be possible in xenograft models
using ERa+/PR+ human breast cancer cell lines. Thus,
this model not only allows one to study the entire devel-
opmental program of luminal mammary tumorigenesis
but also permits short-term experiments using a tumor
cell transplantation approach. For these reasons, the
STAT1-/- mammary tumor is an exceptional model for
human ERa+ PR+ luminal breast cancers.
Conclusions
The important findings of this study are that loss of
STAT1 expression is a frequent event during the pro-
gression of human breast cancers and that loss of func-
tional STAT1 in mice causes spontaneous development
of mammary adenocarcinomas. These murine STAT1-/-
mammary tumors closely recapitulate the progression
and biology of human ERa+ luminal breast cancers.
This is underscored by the potent anti-tumor action of
ovarian ablation therapy on the STAT1-/- mammary
tumors. Our results thus validate the physiological rele-
vance of our novel mouse ERa+/PR+ STAT1-/- mam-
mary tumors for potential translatability to human
breast cancer research.
Additional material
Additional file 1: Supplementary Figure 1. Evidence against
translocation of endogenous murine mammary tumor virus (MMTV)
as the cause of STAT1-/- mammary tumorigenesis. Southern blot
analysis was used to detect the translocation of MMTV long terminal
repeats (LTR). Genomic DNA was harvested from nontransformed
mammary glands of young or aged nulliparous STAT1-/- mice (lanes 2, 3,
12, and 13), nontransformed mammary glands of retired STAT1-/-
breeders (lanes 4 and 14), primary STAT1-/- mammary tumors (lanes 6, 7,
16, and 17), or SSM cell lines established from primary STAT1-/- mammary
tumors (lanes 8 to 10 and lanes 18 to 20) and digested with either EcoRI
(lanes 1 to 10) or PvuII (lanes 11 to 20). The number and the sizes of the
DNA fragments hybridized to the MMTV LTR in these samples are
indistinguishable from those in WT mammary glands (lanes 1 and 11)
and STAT1-/- splenocytes (lanes 5 and 15), arguing against an association
between MMTV LTR translocation and mammary tumorigenesis in
STAT1-/- mammary glands.
Additional file 2: Supplementary Figure 2. Establishment of
Spontaneous STAT1-/- Mammary (SSM) epithelial tumor cell lines.
(A) Primary STAT1-/- mammary tumors were mechanically dissociated
and then digested in collagenese solution. Disaggregated tumor and
stromal cells were analyzed for the expression of cytokeratin as a marker
for epithelial cells (green) and vimentin as a marker for mesenchymal
cells (red) by immunofluoresence. Freshly disaggregated tumors were
comprised of epithelial tumor cells (green) and stromal fibroblasts (red).
(B, C, and D) Epithelial tumor cell lines SSM1 (B), SSM2 (C), and SSM3
(D) are devoid of stromal fibroblasts as evidenced by the complete
absence of vimentin-positive cells. Representative images from 8
independent experiments.
Additional file 3: This file contains the expression values of 96
genes that were used in Figure 8to classify 232 human breast
cancer datasets, 13 mouse mammary models datasets and primary
STAT1-/- mammary tumors.
Abbreviations
CK: cytokeratin; DAPI: 4’-6-diamidino-2-phenylindole; DMEM/F12: Dulbecco’s
modified Eagle’s medium/F12; E2: estradiol; ERα: estrogen receptor-alpha;
FBS: fetal bovine serum; H&E: hematoxylin and eosin; HER2: human
epidermal growth factor receptor 2; IFN: interferon; IQR: interquartile range;
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progesterone receptor; S1N: STAT1-null; Ser: serine; SSM: spontaneous
STAT1-/- mammary (epithelial tumor cell line); Tyr: tyrosine; WT: wild-type.
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